Skip to main content

Table 3 Univariate analysis for progression-free survival

From: Outcome of lung metastases due to bone giant cell tumor initially managed with observation

Variable No. of patients 5-year progression-free survival (95% CI) (%) p value
Age (years)
 < 30 11 36.4 (14.3–66.1) 0.116
 30 ≤ 11 60.6 (29.7–84.8)
Sex
 Male 6 88.3 (36.9–97.7) 0.066
 Female 16 32.8 (13.0–61.4)
Site
 Distal radius 5 40.0 (10.0–80.0) 0.926
 Other sites 17 52.9 (30.3–74.5)
Campanacci classification
 Stage II 4 50.0 (12.3–87.7) 0.913
 Stage III 18 48.6 (26.7–71.0)
Previous surgery
 No 15 60.0 (34.8–80.8) 0.260
 Yes 7 28.6 (7.2–67.3)
Lung metastasis at presentation
 No 16 56.3 (32.4–77.5) 0.502
 Yes 6 25.0 (3.8–73.8)
Pathological fracture at presentation
 No 16 41.7 (20.2–66.9) 0.187
 Yes 6 66.7 (26.8–91.6)
Surgery for primary tumor
 Curettage 6 50.0 (16.8–83.2) 0.769
 Resection 16 50.0 (27.3–72.7)
Pre- and postoperative denosumab treatment
 No 18 55.6 (33.0–76.0) 0.376
 Yes 4 25.0 (3.4–76.2)
Local recurrence
 None 12 41.7 (18.5–69.2) 0.462
 ≥ 1 10 56.0 (24.7–83.2)
Interval between surgery of primary tumor and occurrence of lung metastasis (months)
 < 24 13 34.6 (13.2–64.8) 0.399
 24 ≤ 9 66.7 (33.3–88.9)
Number of nodules
 < 4 7 57.1 (23.0–85.6) 0.397
 4 ≤ 9 44.4 (17.7–74.9)
Lung lesion
 Solitary 2 100.0 0.224
 Multiple 20 43.8 (23.9–65.8)
Laterality
 Unilateral 3 66.7 (15.3–95.7) 0.617
 Bilateral 19 46.1 (25.2–68.3)
Size of maximum nodule (mm)
 ≤ 5 11 63.6 (33.9–85.7) 0.022*
 5 < 5 40.0 (10.0–80.0)
  1. *The difference was significant